{"id":4016,"date":"2023-07-21T09:37:50","date_gmt":"2023-07-21T07:37:50","guid":{"rendered":"https:\/\/www.amyloidosisalliance.org\/wichtige-pressemitteilung\/"},"modified":"2026-11-03T10:19:01","modified_gmt":"2026-11-03T09:19:01","slug":"wichtige-pressemitteilung","status":"publish","type":"post","link":"https:\/\/www.amyloidosisalliance.org\/de\/wichtige-pressemitteilung\/","title":{"rendered":"Wichtige Pressemitteilung"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Eine gro\u00dfartige Nachricht f\u00fcr die Gemeinschaft!! <br\/><br\/>Diese Pressemitteilung gibt bekannt, dass das Unternehmen BioBridge nun einen Zulassungsantrag bei den Gesundheitsbeh\u00f6rden einreichen kann. <br\/>Das braucht Zeit, und die Behandlung wird nicht so bald verf\u00fcgbar sein.<\/p>\n\n<p class=\"wp-block-paragraph\"><br\/>Die vollst\u00e4ndigen Ergebnisse werden in einem Monat auf dem ESC-Kongress in Amsterdam vorgestellt.<br\/>Eine neue Behandlung ist eine gute Nachricht, und wir hoffen, dass sie in allen L\u00e4ndern f\u00fcr alle Patienten verf\u00fcgbar sein wird. <\/p>\n\n<p class=\"wp-block-paragraph\">Beim Zugang zu Behandlungen gibt es noch immer zu viel Ungleichheit.<\/p>\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2023\/07\/BridgeBio-Press-Release-ATTRibute-CM-30-Month-Data.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Einbettung von BridgeBio-Press-Release.\"><\/object><a id=\"wp-block-file--media-2a54c423-6ba6-434f-9ac5-0f4917b3d978\" href=\"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2023\/07\/BridgeBio-Press-Release-ATTRibute-CM-30-Month-Data.pdf\">BridgeBio-Press-Release<\/a><a href=\"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2023\/07\/BridgeBio-Press-Release-ATTRibute-CM-30-Month-Data.pdf\" class=\"wp-block-file__button wp-element-button\" download=\"\" aria-describedby=\"wp-block-file--media-2a54c423-6ba6-434f-9ac5-0f4917b3d978\">T\u00e9l\u00e9charger<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ein Unternehmen k\u00fcndigt an, eine Behandlung der ATTR-Amyloidose bei den Gesundheitsbeh\u00f6rden einreichen zu k\u00f6nnen. Der Zugang zur Behandlung muss nun die Patienten in allen L\u00e4ndern erreichen.<\/p>\n","protected":false},"author":1,"featured_media":4017,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[40],"tags":[],"class_list":["post-4016","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized-de"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Wichtige Pressemitteilung<\/title>\n<meta name=\"description\" content=\"Ein Unternehmen k\u00fcndigt an, eine Behandlung der ATTR-Amyloidose bei den Gesundheitsbeh\u00f6rden einreichen zu k\u00f6nnen. Der Zugang zur Behandlung muss nun die Patienten in allen L\u00e4ndern erreichen.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.amyloidosisalliance.org\/de\/wichtige-pressemitteilung\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wichtige Pressemitteilung\" \/>\n<meta property=\"og:description\" content=\"Ein Unternehmen k\u00fcndigt an, eine Behandlung der ATTR-Amyloidose bei den Gesundheitsbeh\u00f6rden einreichen zu k\u00f6nnen. Der Zugang zur Behandlung muss nun die Patienten in allen L\u00e4ndern erreichen.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.amyloidosisalliance.org\/de\/wichtige-pressemitteilung\/\" \/>\n<meta property=\"og:site_name\" content=\"Amyloidosis Alliance\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/AmyloidosisAlliance\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-21T07:37:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-03T09:19:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Publication-Instagram-3-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@amyloidosisa\" \/>\n<meta name=\"twitter:site\" content=\"@amyloidosisa\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/wichtige-pressemitteilung\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/wichtige-pressemitteilung\\\/\"},\"author\":{\"name\":\"Amyloidosis Alliance\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/#organization\"},\"headline\":\"Wichtige Pressemitteilung\",\"datePublished\":\"2023-07-21T07:37:50+00:00\",\"dateModified\":\"2026-11-03T09:19:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/wichtige-pressemitteilung\\\/\"},\"wordCount\":93,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/wichtige-pressemitteilung\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Publication-Instagram-3-1.png\",\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/wichtige-pressemitteilung\\\/\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/wichtige-pressemitteilung\\\/\",\"name\":\"Wichtige Pressemitteilung\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/wichtige-pressemitteilung\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/wichtige-pressemitteilung\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Publication-Instagram-3-1.png\",\"datePublished\":\"2023-07-21T07:37:50+00:00\",\"dateModified\":\"2026-11-03T09:19:01+00:00\",\"description\":\"Ein Unternehmen k\u00fcndigt an, eine Behandlung der ATTR-Amyloidose bei den Gesundheitsbeh\u00f6rden einreichen zu k\u00f6nnen. Der Zugang zur Behandlung muss nun die Patienten in allen L\u00e4ndern erreichen.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/wichtige-pressemitteilung\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/wichtige-pressemitteilung\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/wichtige-pressemitteilung\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Publication-Instagram-3-1.png\",\"contentUrl\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Publication-Instagram-3-1.png\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/wichtige-pressemitteilung\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/startseite\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wichtige Pressemitteilung\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/\",\"name\":\"Amyloidosis Alliance\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/#organization\",\"name\":\"Amyloidosis Alliance\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/logo.png\",\"contentUrl\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/logo.png\",\"width\":252,\"height\":252,\"caption\":\"Amyloidosis Alliance\"},\"image\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/AmyloidosisAlliance\\\/\",\"https:\\\/\\\/x.com\\\/amyloidosisa\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Wichtige Pressemitteilung","description":"Ein Unternehmen k\u00fcndigt an, eine Behandlung der ATTR-Amyloidose bei den Gesundheitsbeh\u00f6rden einreichen zu k\u00f6nnen. Der Zugang zur Behandlung muss nun die Patienten in allen L\u00e4ndern erreichen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.amyloidosisalliance.org\/de\/wichtige-pressemitteilung\/","og_locale":"de_DE","og_type":"article","og_title":"Wichtige Pressemitteilung","og_description":"Ein Unternehmen k\u00fcndigt an, eine Behandlung der ATTR-Amyloidose bei den Gesundheitsbeh\u00f6rden einreichen zu k\u00f6nnen. Der Zugang zur Behandlung muss nun die Patienten in allen L\u00e4ndern erreichen.","og_url":"https:\/\/www.amyloidosisalliance.org\/de\/wichtige-pressemitteilung\/","og_site_name":"Amyloidosis Alliance","article_publisher":"https:\/\/www.facebook.com\/AmyloidosisAlliance\/","article_published_time":"2023-07-21T07:37:50+00:00","article_modified_time":"2026-11-03T09:19:01+00:00","og_image":[{"width":1080,"height":1080,"url":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Publication-Instagram-3-1.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_creator":"@amyloidosisa","twitter_site":"@amyloidosisa","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.amyloidosisalliance.org\/de\/wichtige-pressemitteilung\/#article","isPartOf":{"@id":"https:\/\/www.amyloidosisalliance.org\/de\/wichtige-pressemitteilung\/"},"author":{"name":"Amyloidosis Alliance","@id":"https:\/\/www.amyloidosisalliance.org\/de\/#organization"},"headline":"Wichtige Pressemitteilung","datePublished":"2023-07-21T07:37:50+00:00","dateModified":"2026-11-03T09:19:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.amyloidosisalliance.org\/de\/wichtige-pressemitteilung\/"},"wordCount":93,"commentCount":0,"publisher":{"@id":"https:\/\/www.amyloidosisalliance.org\/de\/#organization"},"image":{"@id":"https:\/\/www.amyloidosisalliance.org\/de\/wichtige-pressemitteilung\/#primaryimage"},"thumbnailUrl":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Publication-Instagram-3-1.png","inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.amyloidosisalliance.org\/de\/wichtige-pressemitteilung\/","url":"https:\/\/www.amyloidosisalliance.org\/de\/wichtige-pressemitteilung\/","name":"Wichtige Pressemitteilung","isPartOf":{"@id":"https:\/\/www.amyloidosisalliance.org\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.amyloidosisalliance.org\/de\/wichtige-pressemitteilung\/#primaryimage"},"image":{"@id":"https:\/\/www.amyloidosisalliance.org\/de\/wichtige-pressemitteilung\/#primaryimage"},"thumbnailUrl":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Publication-Instagram-3-1.png","datePublished":"2023-07-21T07:37:50+00:00","dateModified":"2026-11-03T09:19:01+00:00","description":"Ein Unternehmen k\u00fcndigt an, eine Behandlung der ATTR-Amyloidose bei den Gesundheitsbeh\u00f6rden einreichen zu k\u00f6nnen. Der Zugang zur Behandlung muss nun die Patienten in allen L\u00e4ndern erreichen.","breadcrumb":{"@id":"https:\/\/www.amyloidosisalliance.org\/de\/wichtige-pressemitteilung\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.amyloidosisalliance.org\/de\/wichtige-pressemitteilung\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.amyloidosisalliance.org\/de\/wichtige-pressemitteilung\/#primaryimage","url":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Publication-Instagram-3-1.png","contentUrl":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Publication-Instagram-3-1.png","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/www.amyloidosisalliance.org\/de\/wichtige-pressemitteilung\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.amyloidosisalliance.org\/de\/startseite\/"},{"@type":"ListItem","position":2,"name":"Wichtige Pressemitteilung"}]},{"@type":"WebSite","@id":"https:\/\/www.amyloidosisalliance.org\/de\/#website","url":"https:\/\/www.amyloidosisalliance.org\/de\/","name":"Amyloidosis Alliance","description":"","publisher":{"@id":"https:\/\/www.amyloidosisalliance.org\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.amyloidosisalliance.org\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.amyloidosisalliance.org\/de\/#organization","name":"Amyloidosis Alliance","url":"https:\/\/www.amyloidosisalliance.org\/de\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.amyloidosisalliance.org\/de\/#\/schema\/logo\/image\/","url":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/logo.png","contentUrl":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/logo.png","width":252,"height":252,"caption":"Amyloidosis Alliance"},"image":{"@id":"https:\/\/www.amyloidosisalliance.org\/de\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/AmyloidosisAlliance\/","https:\/\/x.com\/amyloidosisa"]}]}},"_links":{"self":[{"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/posts\/4016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/comments?post=4016"}],"version-history":[{"count":1,"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/posts\/4016\/revisions"}],"predecessor-version":[{"id":4018,"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/posts\/4016\/revisions\/4018"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/media\/4017"}],"wp:attachment":[{"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/media?parent=4016"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/categories?post=4016"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/de\/wp-json\/wp\/v2\/tags?post=4016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}